Search

  3. ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

    Press release

    … ProQR to Present Results from Phase 1/2 Trial of QR-421a for … & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … “Investors and Media” section of the Company’s website, www.ProQR.com .  The dial-in details for the call are +1 …

  6. ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

    Press release

    … ProQR Receives Fast Track Designation from FDA for QR-421a … & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to begin enrollment in …

  7. ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

    Press release

    … ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of … in Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the … Aniz Girach, Ophthalmologist and Chief Medical Officer of ProQR. “With the ongoing trials in LCA10 and Ushers syndrome …